Gross Profit Trends Compared: United Therapeutics Corporation vs Lantheus Holdings, Inc.

Pharma Giants' Profit Battle: United vs. Lantheus

__timestampLantheus Holdings, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141255190001162636000
Thursday, January 1, 20151355220001396725000
Friday, January 1, 20161377800001526100000
Sunday, January 1, 20171621350001619600000
Monday, January 1, 20181748850001429100000
Tuesday, January 1, 20191748110001331200000
Wednesday, January 1, 20201387610001375200000
Friday, January 1, 20211876950001563000000
Saturday, January 1, 20225817030001789600000
Sunday, January 1, 20237095430002070000000
Loading chart...

Unleashing insights

Gross Profit Trends: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, United Therapeutics Corporation and Lantheus Holdings, Inc. have shown distinct trajectories in their gross profit trends over the past decade. From 2014 to 2023, United Therapeutics consistently outperformed Lantheus, with its gross profit peaking at approximately $2.07 billion in 2023, marking a 78% increase from 2014. In contrast, Lantheus Holdings experienced a more volatile journey, with a significant surge in 2022, reaching around $709 million in 2023, a remarkable 465% growth from its 2014 figures. This stark contrast highlights United Therapeutics' steady growth and Lantheus' recent aggressive expansion. As the industry evolves, these trends underscore the strategic decisions and market dynamics shaping each company's financial health.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025